EU Panel Recommends Approval of Zykadia as First-line Treatment for ALK-Positive NSCLC
News
Zykadia (ceritinib) was recommended for approval in Europe by the EMA‘s Committee for Medicinal Products for Human Use (CHMP) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) ... Read more